| Market Cap | 327.32M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -19.86M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 502.00% |
| Sales | 14.81M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 38.00% |
| Dividend | N/A | Price/Book | 6.80 | EPS next 5Y | - | 52W High Chg | -53.00% |
| Recommedations | - | Quick Ratio | 0.39 | Shares Outstanding | 7.53M | 52W Low Chg | 3,718.00% |
| Insider Own | 9.09% | ROA | -27.08% | Shares Float | 6.49M | Beta | 1.40 |
| Inst Own | 1.77% | ROE | -288.71% | Shares Shorted/Prior | -/- | Price | 6.30 |
| Gross Margin | 57.15% | Profit Margin | -134.12% | Avg. Volume | 5 | Target Price | - |
| Oper. Margin | -83.60% | Earnings Date | Oct 3 | Volume | 336 | Change | 570.21% |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
